What is the primary purpose of using leukocyte-reduced blood products?

The primary purpose of using leukocyte-reduced blood products is to prevent transfusion-related febrile reactions. Febrile non-hemolytic transfusion reactions are typically caused by the recipient's immune response to leukocytes present in the transfused blood. By reducing the number of leukocytes in the blood products, these reactions can be significantly minimized. This is particularly important for patients who may require multiple transfusions or those who have had previous reactions, as it helps to improve the safety and comfort of blood transfusions.

Increasing hemoglobin levels, enhancing coagulability, and improving oxygen delivery do not directly relate to the specific benefits of leukocyte reduction. While these aspects are important in the overall clinical context of transfusion medicine, they are not the primary focus of leukocyte reduction, which is specifically aimed at reducing immune responses and related complications.